136 related articles for article (PubMed ID: 24766134)
1. A suicide gene therapy combining the improvement of cyclophosphamide tumor cytotoxicity and the development of an anti-tumor immune response.
Touati W; Tran T; Seguin J; Diry M; Flinois JP; Baillou C; Lescaille G; Andre F; Tartour E; Lemoine FM; Beaune P; de Waziers I
Curr Gene Ther; 2014; 14(3):236-46. PubMed ID: 24766134
[TBL] [Abstract][Full Text] [Related]
2. Engineered mesenchymal stem cells as vectors in a suicide gene therapy against preclinical murine models for solid tumors.
Amara I; Pramil E; Senamaud-Beaufort C; Devillers A; Macedo R; Lescaille G; Seguin J; Tartour E; Lemoine FM; Beaune P; de Waziers I
J Control Release; 2016 Oct; 239():82-91. PubMed ID: 27565211
[TBL] [Abstract][Full Text] [Related]
3. A virus-directed enzyme prodrug therapy (VDEPT) strategy for lung cancer using a CYP2B6/NADPH-cytochrome P450 reductase fusion protein.
Tychopoulos M; Corcos L; Genne P; Beaune P; de Waziers I
Cancer Gene Ther; 2005 May; 12(5):497-508. PubMed ID: 15746946
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene.
Chen L; Yu LJ; Waxman DJ
Cancer Res; 1997 Nov; 57(21):4830-7. PubMed ID: 9354446
[TBL] [Abstract][Full Text] [Related]
5. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy.
Jounaidi Y; Waxman DJ
Cancer Res; 2000 Jul; 60(14):3761-9. PubMed ID: 10919648
[TBL] [Abstract][Full Text] [Related]
6. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene.
Chen L; Waxman DJ; Chen D; Kufe DW
Cancer Res; 1996 Mar; 56(6):1331-40. PubMed ID: 8640822
[TBL] [Abstract][Full Text] [Related]
7. Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy.
Jounaidi Y; Waxman DJ
Cancer Res; 2001 Jun; 61(11):4437-44. PubMed ID: 11389073
[TBL] [Abstract][Full Text] [Related]
8. Enhanced bystander cytotoxicity of P450 gene-directed enzyme prodrug therapy by expression of the antiapoptotic factor p35.
Schwartz PS; Chen CS; Waxman DJ
Cancer Res; 2002 Dec; 62(23):6928-37. PubMed ID: 12460909
[TBL] [Abstract][Full Text] [Related]
9. Adenoviral delivery of pan-caspase inhibitor p35 enhances bystander killing by P450 gene-directed enzyme prodrug therapy using cyclophosphamide+.
Doloff JC; Su T; Waxman DJ
BMC Cancer; 2010 Sep; 10():487. PubMed ID: 20836875
[TBL] [Abstract][Full Text] [Related]
10. A cytochrome P450 2B6 meditated gene therapy strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4N.
McErlane V; Yakkundi A; McCarthy HO; Hughes CM; Patterson LH; Hirst DG; Robson T; McKeown SR
J Gene Med; 2005 Jul; 7(7):851-9. PubMed ID: 15712360
[TBL] [Abstract][Full Text] [Related]
11. Use of replication-conditional adenovirus as a helper system to enhance delivery of P450 prodrug-activation genes for cancer therapy.
Jounaidi Y; Waxman DJ
Cancer Res; 2004 Jan; 64(1):292-303. PubMed ID: 14729637
[TBL] [Abstract][Full Text] [Related]
12. Impact of liver P450 reductase suppression on cyclophosphamide activation, pharmacokinetics and antitumoral activity in a cytochrome P450-based cancer gene therapy model.
Huang Z; Raychowdhury MK; Waxman DJ
Cancer Gene Ther; 2000 Jul; 7(7):1034-42. PubMed ID: 10917206
[TBL] [Abstract][Full Text] [Related]
13. Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy.
Jounaidi Y; Hecht JE; Waxman DJ
Cancer Res; 1998 Oct; 58(19):4391-401. PubMed ID: 9766669
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer.
Chen L; Waxman DJ
Curr Pharm Des; 2002; 8(15):1405-16. PubMed ID: 12052216
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Bystander Cell Killing Effects in Suicide Gene Therapy of Cancer: Engineered Thymidylate Kinase (TMPK)/AZT Enzyme-Prodrug Axis.
Sato T; Neschadim A; Nakagawa R; Yanagisawa T; Medin JA
Methods Mol Biol; 2015; 1317():55-67. PubMed ID: 26072401
[TBL] [Abstract][Full Text] [Related]
16. Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11.
Jounaidi Y; Chen CS; Veal GJ; Waxman DJ
Mol Cancer Ther; 2006 Mar; 5(3):541-55. PubMed ID: 16546968
[TBL] [Abstract][Full Text] [Related]
17. Improvement of cyclophosphamide activation by CYP2B6 mutants: from in silico to ex vivo.
Nguyen TA; Tychopoulos M; Bichat F; Zimmermann C; Flinois JP; Diry M; Ahlberg E; Delaforge M; Corcos L; Beaune P; Dansette P; André F; de Waziers I
Mol Pharmacol; 2008 Apr; 73(4):1122-33. PubMed ID: 18212249
[TBL] [Abstract][Full Text] [Related]
18. Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450.
Chen CS; Jounaidi Y; Waxman DJ
Drug Metab Dispos; 2005 Sep; 33(9):1261-7. PubMed ID: 15919850
[TBL] [Abstract][Full Text] [Related]
19. Genetically modified macrophages expressing hypoxia regulated cytochrome P450 and P450 reductase for the treatment of cancer.
Kan O; Day D; Iqball S; Burke F; Grimshaw MJ; Naylor S; Binley K
Int J Mol Med; 2011 Feb; 27(2):173-80. PubMed ID: 21165551
[TBL] [Abstract][Full Text] [Related]
20. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
Roy P; Waxman DJ
Toxicol In Vitro; 2006 Mar; 20(2):176-86. PubMed ID: 16293390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
